Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Molecular Partners Radio-DARPin Therapy Candidate MP0712 Supported By In Vivo Data Presented At The European Association Of Nuclear Medicine Congress; First-In-Human Start And Initial Clinical Data Expected In 2025
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025
Radio-DARPin疗法（RDT）候选药物MP0712得到在欧洲核医学协会（EANM）大会上展示的体内数据支持；首批人体试验预计将于2025年开始，初步临床数据预计在2025年公布
RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712
RDt与Orano Med的战略协议经过修订和强化：两家公司将共同开发四种基于212Pb的RDt候选药物，包括MP0712
MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual Meeting (ASH); protocol being amended to improve treatment exposure
MP0533相位1剂量递增研究继续进行；更新将在美国血液学年会（ASH）上呈现；为改善治疗效果正在修订方案
CD3 Switch-DARPin proof-of-mechanism to be presented at the Society for the Immunotherapy of Cancer Annual Meeting (SITC); update on Switch-DARPin MP0621 to be presented at ASH
CD3 Switch-DARPin机制验证将在免疫治疗年会（SITC）上呈现；Switch-DARPin MP0621的更新将在ASH上呈现
MP0317 Phase 1 biomarker data presented at the International Cancer Immunotherapy Conference (CICON); additional biomarker data to be shared at SITC
MP0317相位1生物标志数据在国际癌症免疫治疗大会（CICON）上展示；额外生物标志数据将在SITC上分享
Outlook: Funded into 2027 with cash and short-term time deposits of CHF 143.6 million as of September 30, 2024, Molecular Partners expects total operating expenses of CHF 65-70 million in 2024.
展望：截至2024年9月30日，Molecular Partners通过瑞士法郎14360万现金及短期存款融资到2027年，预计2024年总营业费用为6500-7000万瑞士法郎
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the third quarter of 2024.
2024年10月31日（全球新闻社）——瑞士苏黎世州兹里根（Zurich-Schlieren）和美国马萨诸塞州康科德（Concord）——根据第53条收益法定规定的即时公告——临床阶段生物技术公司Molecular Partners AG（SIX：MOLN，纳斯达克：MOLN）今天宣布了2024年第三季度企业亮点和未经审计的财务业绩
"In the last quarter we continued to execute our plan to bring our first Radio-DARPin program to IND submission, and into the clinics. DLL3 remains a highly interesting target that is gaining significant attention. Our team presented additional preclinical data showing that MP0712 is safe and efficacious in a highly relevant tumor model, with DLL3 expression levels matching those in human tumors," said Patrick Amstutz, Ph.D., Molecular Partners' Chief Executive Officer. "In addition, we strengthened our relationship with our partner Orano Med, ensuring that both parties will have the opportunity to bring two Radio-DARPin products to market, for a total of four. Lastly our recent capital raise allows us additional financial flexibility into 2027 with participation from new, specialized investors and supportive existing investors."
“在上个季度中，我们继续执行计划，推动我们的首个Radio-DARPin项目提交IND，并进入临床试验。 DLL3仍然是一个备受关注的高度有趣的靶点。我们的团队展示了额外的临床前数据，表明MP0712在极具相关性的肿瘤模型中安全有效，DLL3表达水平与人类肿瘤中的水平相匹配，”Molecular Partners首席执行官Patrick Amstutz博士表示。 “此外，我们与合作伙伴Orano Med的关系得到加强，确保双方将有机会推出两种Radio-DARPin产品，共计四种。最近的资本增资使我们在拥有来自新的专业投资者和支持性现有投资者的参与下，进一步提高了2027年的财务灵活性。”
